Search by Drug Name or NDC

    NDC 63323-0193-52 Irinotecan Hydrochloride 20 mg/mL Details

    Irinotecan Hydrochloride 20 mg/mL

    Irinotecan Hydrochloride is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Fresenius Kabi USA, LLC. The primary component is IRINOTECAN HYDROCHLORIDE.

    Product Information

    NDC 63323-0193
    Product ID 63323-193_4e0a18c8-35aa-447c-bd91-b81d7d494d8e
    Associated GPIs 21550040102025 21550040102030
    GCN Sequence Number 062173
    GCN Sequence Number Description irinotecan HCl VIAL 40 MG/2 ML INTRAVEN
    HIC3 V3E
    HIC3 Description ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS
    GCN 97955
    HICL Sequence Number 010778
    HICL Sequence Number Description IRINOTECAN HCL
    Brand/Generic Generic
    Proprietary Name Irinotecan Hydrochloride
    Proprietary Name Suffix n/a
    Non-Proprietary Name IRINOTECAN HYDROCHLORIDE
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 20
    Active Ingredient Units mg/mL
    Substance Name IRINOTECAN HYDROCHLORIDE
    Labeler Name Fresenius Kabi USA, LLC
    Pharmaceutical Class Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA077776
    Listing Certified Through 2024-12-31

    Package

    NDC 63323-0193-52 (63323019352)

    NDC Package Code 63323-193-52
    Billing NDC 63323019352
    Package 1 VIAL in 1 BOX (63323-193-52) / 2 mL in 1 VIAL
    Marketing Start Date 2009-04-01
    NDC Exclude Flag N
    Pricing Information N/A